icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
kBesCVd3VBu2JAEq
Listen
